Kaiser permanente Colorado region pharmacy department: Innovative leader in pharmacy practice

Journal of the American Pharmacists Association

Volumn 46, Issue 1, 2006, Pages 67-76

  Helling, Dennis K ^a,b   Nelson, Kent M ^c   Ramirez, Jairo E ^a   Humphries, Tammy L ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Kaiser Permanente Colorado Region ^*

Author keywords

Automation; Clinical pharmacy services; Community and ambulatory pharmacy; Hospital pharmacy; Managed care; Medication use management; Pharmacy practice; Technology

Indexed keywords

ARTICLE; CLINICAL PHARMACY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HOSPITAL PHARMACY; HUMAN; MEDICAL PRACTICE; MEDICAL SPECIALIST; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN; PUBLIC HEALTH SERVICE; UNITED STATES; CONTINUING EDUCATION; DRUG INFORMATION; HEALTH CARE QUALITY; HEALTH MAINTENANCE ORGANIZATION; INFORMATION SYSTEM; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PATIENT SATISFACTION; PHARMACY; PRIMARY HEALTH CARE; TRAVEL;

ANTICOAGULANT AGENT;

ANTICOAGULANTS; BIOMEDICAL RESEARCH; COLORADO; DRUG INFORMATION SERVICES; EDUCATION, CONTINUING; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INFORMATION SYSTEMS; PATIENT SATISFACTION; PHARMACEUTICAL SERVICES; PRIMARY HEALTH CARE; QUALITY ASSURANCE, HEALTH CARE; TRAVEL;

EID: 33645528383     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434506775268580     Document Type: Article

References (25)

1. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med. 2000;160:2926-32.
2. Merenich JA, Lousberg TR, Brennan SH, Calonge NB. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente Experience). Am J Cardiol. 2000;85:36A-42A.
3. Witt DM, Tillman DJ. Clinical pharmacy anticoagulation services in a group model health maintenance organization. Pharm Pract Manag Q. 1998;18:34-55.
4. Helling DK, Nelson KM. How to develop and implement a program to continuously demonstrate the value of clinical pharmacy services. Pharmacotherapy. 2000;20:340S-343S.
5. Witt DM, Lyons E, Beall DG, et al. A controlled retrospective evaluation of a clinical pharmacy anticoagulation service [abstract]. Pharmacotherapy. 1996;16:514.
6. Lousberg T, Witt D, Beall D, et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med. 1998;158:528-34.
7. Witt DM, Humphries TL. A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care. J Thromb Thrombolysis. 2003;15:113-8.
8. Patel RJ, Witt DM, Saseen JJ, et al. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy. 2000;20:1159-66.
9. Ansell JE, Buttaro ML, Thomas OV, et al. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother. 1997;31:604-14.
10. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med. 1998;158:1641-7.
11. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127:1515-22.
12. Stubbings T, Miller C, Humphries TL, et al. Telepharmacy-a unique approach to the delivery of pharmaceutical care. Kaiser Permanente Colorado Region Clinical Pharmacy Call Center. Am J Health Syst Pharm. 2005;62:406-10.
13. Jackson AB, Humphries TL, Nelson KM, Helling DK. Clinical pharmacy travel medicine services: a new frontier. Ann Pharmacother. 2004;38:2160-5.
14. Miller K, Raebel M. Improving influenza and pneumococcal immunization rates among adults receiving clinical pharmacy services in a group model health maintenance organization [abstract]. Pharmacotherapy. 2000;20:337.
15. McConnell KJ, Humphries TL, Raebel MA, Merenich JA. Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Pharmacotherapy. 2003;23:1564-72.
16. Shanahan RL, Kerzee JA, Sandhoff BG, et al. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy. 2005;25:345-51.
17. Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618-24.
18. Hitchcock AM, Lousberg TR, Merenich J. The impact of clinical pharmacy management on cardiovascular risk reduction in patients with established heart disease in a group model health maintenance organization (abstract). Pharmacotherapy. 2000;20:360-1.
19. Olson KL, Rasmussen J, Sandhoff BG, Merenich JA. A population-wide approach to lipid management of 8,014 patients with coronary artery disease by a clinical pharmacy cardiac risk service. Arch Intern Med. 2005;165:49-54.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
21. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events (CARE) trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.
22. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
23. Carter BL, Helling DK, Anderson J, Raebel M. Description of a formal affiliation between a school of pharmacy and a managed care organization. J Managed Care Pharm. 1999;5:433-7.
24. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990-2002. J Am Coll Cardiol. 2003;41:56-61.
25. Olson KL, Bumgard TJ, Tsuyuki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy. 2001;21:807-17.